Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies.
The business
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Small Caps Research
No research on Telix Pharmaceuticals Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise TLX based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Telix Pharmaceuticals to acquire Canadian isotope innovator ARTMS in $125.9m deal
Australian biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) is set to acquire Canadian radioisotope technology firm ARTMS Inc in a $125.9 million deal designed to boost its supply chain and production capacity. The deal will include ARTMS’ advanced cyclotron-based isotope production platform, a manufacturing plant and a stockpile of ultra-pure rare metals required for consumable target […]
Medibank suffers cyberattack, Telix Pharma expands GE Healthcare partnership and APA Group to acquire Basslink
Health insurance provider Medibank Private’s (ASX: MPL) shares are down this week after the company revealed it suffered a major cyber security incident. Despite the concern, the provider urged there was no evidence of customers’ data being accessed and has since returned to business as usual. Medibank has a large database, covering more than 3.7 […]
Telix withdraws Europe marketing application, AGL to close power station early and BHP prioritises Peru exploration
Telix Pharmaceuticals (ASX: TLX) has announced it has withdrawn its application to market the company’s lead prostate cancer imaging product, Illuccix, in Europe. The Danish Medicines Agency asked for additional chemistry, manufacturing and control data from Telix, but the Australian company said the requests could not be delivered within the prescribed review timeframe. Telix group […]
A2 Milk hopes to join Bubs in alleviating US infant formula crisis, ASIC sues ANZ and Telix Pharma granted pass through
A2 Milk (ASX: A2M) is rallying in its efforts to join rival Bubs Australia (ASX: BUB), which revealed it will export 27.5 million bottles of infant formula products to the United States to help with a nationwide shortage created by the global pandemic. Dual-listed A2 Milk submitted an application to the US Food and Drug […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.